

 Rudolf-Wissell-Str. 28

 37079 Göttingen, Germany

 Phone:
 +49 551-50556-0

 Fax:
 +49 551-50556-384

 E-mail:
 sales@sysy.com

 Web:
 www.sysy.com

GARP

Cat.No. 221 011; Monoclonal mouse antibody, 100 µg purified IgG (lyophilized)

Data Sheet

Reconstitution/ Storage	100 μg purified IgG, lyophilized. Azide was added before lyophilization. For reconstitution add 100 μl H_2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C until use.
Applications	WB: 1 : 1000 (AP staining) IP: not tested yet ICC: not tested yet IHC: not tested yet IHC-P/FFPE: not tested yet
Clone	50G10
Subtype	IgG2b (κ light chain)
Immunogen	Recombinant protein corresponding to AA 23 to 612 from human GARP (UniProt Id: Q14392)
Epitop	Epitop: AA 23 to 612 from human GARP (UniProt Id: Q14392)
Reactivity	Reacts with: human (Q14392). Other species not tested yet.
Specificity	Specific for GARP.
Remarks	Skimmed milk is required for efficient blocking.

TO BE USED IN VITRO / FOR RESEARCH ONLY NOT TOXIC, NOT HAZARDOUS, NOT INFECTIOUS, NOT CONTAGIOUS

Regulatory T-cells (T_{reg} -cells) are involved in the homeostasis of immune reactions and tolerance. These specialized T-cells suppress auto-reactive cells and inhibit autoimmunity. Development and function of T_{reg} -cells depend on the expression of the transcription factor FOX3P. The orphan receptor **GARP**, also referred to as **LRRC 32**, is exclusively found on T_{reg} -cells upon stimulation with anti-CD3/IL-2 or anti-CD3/anti-CD28/IL-2. Additionally it has been shown, that ectopic GARP expression strongly induces FOXP3.

Selected References SYSY Antibodies

GARP: a key receptor controlling FOXP3 in human regulatory T cells.

Probst-Kepper M, Geffers R, Kröger A, Viegas N, Erck C, Hecht HJ, Lünsdorf H, Roubin R, Moharregh-Khiabani D, Wagner K, Ocklenburg F, et al.

Journal of cellular and molecular medicine (2009) 13(9B): 3343-57. WB

Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo.

Cuende J, Liénart S, Dedobbeleer O, van der Woning B, De Boeck G, Stockis J, Huygens C, Colau D, Somja J, Delvenne P, Hannon M, et al.

Science translational medicine (2015) 7(284): 284ra56.

Selected General References

Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning. Pilat N, Baranyi U, Klaus C, Jaeckel E, Mpofu N, Wrba F, Golshayan D, Muehlbacher F, Wekerle T American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2010) 10(4): 751-62.

The Tregs' world according to GARP. Battaglia M, Roncarolo MG European journal of immunology (2009) 39(12): 3296-300.

Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression. Wang R, Wan Q, Kozhaya L, Fujii H, Unutmaz D PloS one (2008) 3(7): e2705.

CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Valencia X, Lipsky PE Nature clinical practice. Rheumatology (2007) 3(11): 619-26.